Three-Drug Combination Extends Survival for Patients with Multiple Myeloma

| February 10, 2017 | 0 Comments
Three-Drug Combination Extends Survival for Patients with Multiple Myeloma

A phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.
See Original Article

Grantee Spotlight: Joseph Kofi Agyin, PhD, MBA – Exploring Bone-Targeted Proteasome Inhibitors to Cure Multiple Myeloma

Dr. Joseph Kofi Agyin, a CRCHD R21 Grantee, is studying the design and synthesis of bone-targeted proteasome inhibitors for treating multiple myeloma.
See Original Article

Grantee Spotlight: Jennie Williams, Ph.D. – Investigating Genetic Biomarkers for Colon Cancer in African Americans

Dr. Jeannie Williams is investigating, through an NCI-supported R01 grant, what role molecular genetics plays in the initiation of colon cancer in African-Americans and cancer health disparities.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply